New Partnership Kicks Off in Second Quarter of
2024!
KALAMAZOO, Mich., June 18,
2024 /PRNewswire/ -- United Kennel Club
(UKC™), today announced a 2024 partnership with
Librela™ (bedinvetmab injection). Librela™
(bedinvetmab injection) is the first and only monthly injectable
anti-NGF monoclonal antibody therapy for the control of canine
osteoarthritis (OA) pain.
UKC's dedication to dog events for over 125 years has garnered
millions of registered dogs, 20,000 active breeders, more than
2,900 clubs and a variety of industry-leading publications, making
it the leading performance dog sports organization in the
world.
UKC is proud to welcome Librela as the newest sponsor of select
UKC events and programs. UKC dog owners can look forward to this
brand's presence at UKC Classic Events around the country in 2024
as well as in digital media installments on UKC-owned channels.
This partnership will benefit UKC dogs and dog owners via
educational content and providing dog owners the tools to initiate
discussions with their veterinarians regarding if Librela is right
for any of their dogs.
"A well-bred dog is going to have pretty seamless construction
overall, but osteoarthritis can occur from injury and underlying
issues as well. UKC programs also welcome shelter and
mixed-bred dogs in certain segments, so lots of our owners could
have this discussion with their vet if appropriate. Outside of any
awards or ribbons, that's a win for the dogs who need it, so we're
proud to create the space for these conversations," UKC Vice
President Todd Kellam said.
"Dogs of all ages, sizes and breeds can experience OA pain
and in fact, approximately 40% of dogs show signs of
OA.1,2 Signs of OA pain may be easier to detect in older
dogs because they often are more advanced, but the pain can start
at a much younger age. Dogs even as young as 1 year old can develop
the condition," says Dr. Richard
Goldstein, Global Chief Medical Officer, at Zoetis. "It's
important for pet owners to work with their veterinarian to
identify the signs and symptoms of OA pain early so that treatment
options such as Librela can be considered, to give our dogs a
better quality of life."
OA is a chronic and painful condition that causes your dog to
hurt all the time if left untreated. Librela offers long-lasting
pain relief with a once-a-month injection administered by your vet.
UKC dog owners can ask their vet about the newest osteoarthritis
injection for dogs.
IMPORTANT SAFETY INFORMATION: For use in dogs only.
Women who are pregnant, trying to conceive or breastfeeding should
take extreme care to avoid self-injection. Hypersensitivity
reactions, including anaphylaxis, could potentially occur with
self-injection. Librela should not be used in breeding, pregnant or
lactating dogs. Librela should not be administered to dogs with
known hypersensitivity to bedinvetmab. The most common adverse
events reported in a clinical study were urinary tract infections,
bacterial skin infections and dermatitis. See full Prescribing
Information at LibrelaPI.com
References: 1. Anderson KL, Zulch H, O'Neill DG, Meeson
RL, Collins LM. Risk factors for canine osteoarthritis and its
predisposing arthropathies: a systematic review. Front Vet Sci.
2020;7:200. doi:10.3389/fvets.2020.00220 2. Wright A, et al.
Identification of canine osteoarthritis using an owner-reported
questionnaire and treatment monitoring using functional mobility
tests. J Small Anim Pract,
2022. http://doi.org/10.1111/jsap.13500
All Librela trademarks are the property of Zoetis Services
LLC or a related company or a licensor unless otherwise noted. ©
2024 Zoetis Services LLC. All rights reserved. LIB-00373
For more information, visit www.ukcdogs.com and
www.librelavetteam.com
UKC™
Guided by the belief that dogs make a
difference by being the best partner a human can have – in the
field, on the job, or in a competition event, UKC is a community
for people and dogs to pursue excellence together. Founded in 1898,
UKC has been dedicated to enhancing the lives of Dogs That Do
More™, and their owners, by providing essential
resources to help owners and breeders make informed decisions. The
dog-human bond is celebrated through family-friendly programs
highlighting the instincts and heritage of purebred and mixed-breed
dogs alike at over 18,000 licensed events annually.
About Zoetis
As the world's leading animal health
company, Zoetis is driven by a singular purpose: to nurture our
world and humankind by advancing care for animals. After innovating
ways to predict, prevent, detect, and treat animal illness for more
than 70 years, Zoetis continues to stand by those raising and
caring for animals worldwide – from veterinarians and pet owners to
livestock farmers and ranchers. The company's leading portfolio and
pipeline of medicines, vaccines, diagnostics and technologies make
a difference in over 100 countries. A Fortune 500 company, Zoetis
generated revenue of $8.5 billion in
2023 with approximately 14,100 employees. For more information,
visit www.zoetis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/united-kennel-club-announces-partnership-with-librela-302175731.html
SOURCE United Kennel Club